RCEL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AVITA Medical Inc (RCEL) is not a strong buy at this moment for a beginner investor with a long-term horizon. While there are some positive catalysts, the financial performance, recent news, and technical indicators suggest a cautious approach. Holding the stock or waiting for further clarity on reimbursement issues and financial stability would be more prudent.
The MACD is slightly positive but contracting, indicating weak momentum. RSI is neutral at 34.35, showing no clear signal. Moving averages are converging, and the stock is trading below key support levels (S1: 4.451, S2: 4.088), suggesting bearish sentiment.
Analysts from Northland see a buying opportunity with a $10 price target, citing easing reimbursement uncertainty and potential for 20%+ topline growth. Hedge funds are significantly increasing their positions, with a 534.61% rise in buying activity last quarter.
Recent news highlights potential securities fraud investigations and reimbursement challenges impacting demand for the company's ReCell product. The stock has also experienced a significant drop in price due to financial health concerns. Technical indicators and stock trend analysis suggest short-term bearish sentiment.
In 2025/Q4, revenue dropped by 4.30% YoY to $17.615M. Net income slightly improved but remained negative at -$11.621M. EPS declined by 13.64% YoY to -0.38, and gross margin dropped by 6.97% to 81.9%. Overall, the financial performance indicates challenges in growth and profitability.
Northland has an Outperform rating with a $10 price target, citing potential for double-digit revenue growth and cash breakeven by FY27. However, these projections depend on resolving reimbursement and financial challenges.
